PPT-Characterizing the health and financial costs of measles and rubella

Dr Kimberly M Thompson Kid Risk Inc wwwkidriskorg Topics Context I ntegrated dynamic disease and economic modeling Discussion httpwwwwprowhointvietnamtopicsimmunizationmeaslesrubellameaslesrubellabigpngua1. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Panel 01502. Vicki Stambos. The 13. th. Global Measles and Rubella Laboratory Network Meeting, Geneva, Switzerland, 29. th. June to 1. st. July 2015. Vicki Stambos. Accelerating Progress Towards Measles and Rubella Control and Elimination Meeting. WHO Western Pacific Region. UNICEF East Asia and Pacific Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 2003. : Measles elimination to be used to strengthen routine immunization . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . . Accelerating Progress towards Measles/Rubella Control and Elimination Goals Meeting. Geneva, Switzerland. June 19, 2016. Lance Rodewald. WHO China Country Office. Measles and Rubella Vaccination Schedule. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. . Mona Aryal. HOD, Health Service Department. Nepal Red Cross Society. National Headquarter. . Nepal Red Cross Society’s Initiative. Vision: . to . provide immediate relief to human suffering and reduce vulnerability, under the Fundamental Principles of the Red Cross, . Dr. Khin Devi Aung. Gavi Secretariat. 21. . June 2016, Geneva. 1. #. vaccineswork. AGENDA. About Gavi, the Vaccine Alliance. Gavi’s. support to countries. Gavi’s. 2016-2020 Strategy. Gavi’s. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Programme:Update. Stefano Malvolti . September 2015, Washington DC. Page: . 1. Reach every child. . MANY . REGIONS AT . RISK . / OFF . TRACK FROM MEASLES ELIMINATION GOALS. Source: . WHO . Source: WHO/UNICEF coverage estimates . Measles and Rubella Annual Partners Meeting, September 15-16 2015. Background. The MRI FRR is developed by the M&RI FRR/RMAWG. Country population data is drawn from UNDP estimates. Vaccine type and timing of SIAs is from countries . MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C .. Education Department.. Kolkata. . Measles . - . An acute viral infection spread via respiratory secretions or aerosols. leading causes of death . among young children . even though a safe and cost-effective vaccine is available. Source. : ISIS, MESS and country reports. | . *Data as of 1 May 2023.. N=. 18,897. 20,064. 18,971. 13,009. 13,308. 41,663. 91,950. 25,693. 9,318. 14,927. Text. In the last 10 years, there was a downward trend in the notification rate of suspected measles and rubella cases, reaching its lowest point in 2021: .